Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2011-03-02 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce ses résultats pour 2010 et fait un point sur ses produits en développement
Earnings Release Classification · 95% confidence The document is titled "INNATE PHARMA ANNONCE SES RÉSULTATS POUR 2010" (Innate Pharma Announces its 2010 Results) and explicitly states: "Innate Pharma SA (...) annonce aujourd'hui ses résultats financiers pour 2010. Les états financiers consolidés non audités sont joints à ce communiqué." It provides a detailed summary of financial performance (revenus, charges, perte nette, trésorerie) for the fiscal year 2010, including comparative figures for 2009, and includes full financial statements (Bilan, Compte de résultat) in the annexes. This content strongly indicates a comprehensive report of annual financial performance. Although the financial statements are noted as 'non audités' (unaudited), the scope and nature of the disclosure align best with an Annual Report (10-K equivalent for non-US filers, or a comprehensive annual filing). Since '10-K' is the designated code for the official yearly report covering full financial performance, it is the most appropriate classification, despite the French context and the 'non-audited' status mentioned in the press release context (which often precedes the final audited 10-K filing). It is not merely an Earnings Release (ER) as it contains extensive operational and balance sheet details, nor is it a Report Publication Announcement (RPA) because the results and statements are fully detailed within the text, not just announced for release elsewhere. FY 2010
2011-03-02 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) reports 2010 financial results and updates on its drug candidates
Earnings Release Classification · 95% confidence The document is an initial announcement of annual financial results for the year ending December 31, 2010. It contains key financial highlights, a summary income statement, and an update on clinical programs. While it includes an appendix with unaudited financial statements, the document itself is structured as a press release (Earnings Release) issued by the company to report these results to the market. It does not constitute the full audited Annual Report (10-K) but rather the preliminary release of financial performance. FY 2010
2011-03-02 English
Innate Pharma (Euronext Paris: FR0010331421 – IPH) receives a milestone payment for IPH 2201, a monoclonal antibody licensed to Novo Nordisk A/S
Regulatory Filings Classification · 95% confidence The document is a press release dated February 28, 2011, announcing that Innate Pharma received a milestone payment from Novo Nordisk A/S related to the filing of a European trial application for the drug candidate IPH 2201. This type of announcement, detailing specific business developments, licensing events, and financial triggers (milestone payments), is characteristic of a general corporate update or regulatory filing that doesn't fit the specific financial report categories (10-K, IR, ER). Since it is a specific, material corporate announcement that is not a standard financial report, dividend notice, management change, or shareholder vote result, it best fits the general 'Regulatory Filings' (RNS) category as a catch-all for significant, non-standard disclosures, or potentially a Capital/Financing Update (CAP) due to the milestone payment, but RNS is broader for press releases detailing operational/licensing news. Given the content focuses heavily on licensing progress and milestone achievement, RNS is the most appropriate general classification for a press release of this nature that isn't a core financial report.
2011-02-28 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) reçoit un paiement d’étape pour IPH 2201, un anticorps monoclonal licencié à Novo Nordisk A/S
Regulatory Filings Classification · 95% confidence The document is a press release dated February 28, 2011, announcing that Innate Pharma received a milestone payment from Novo Nordisk A/S because a clinical trial application was filed for the drug candidate IPH 2201. The text details the status of collaborative projects, drug mechanisms, and provides company background and a standard disclaimer. This type of announcement, focusing on a specific corporate event (milestone payment triggered by regulatory action) and providing operational updates, is characteristic of an Earnings Release (ER) if it were periodic, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category. Since it is not a full annual report (10-K), an interim report (IR), a management discussion (MDA), or a specific financing/dividend announcement, and it is a formal announcement of a business event, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements. However, given the content is a direct announcement of financial/development progress, it is very similar to an Earnings Release (ER) which covers periodical results/updates, but ER is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a specific, non-periodic business update. Since it is a formal press release detailing business progress and financial triggers, and it is not a specific report itself, RNS is the most appropriate fallback, although it shares characteristics with ER. Given the specific nature of the announcement (milestone payment), it is a significant corporate event announcement. If we strictly follow the definitions, it is not a core financial report, nor a management discussion, nor a capital change. It is a regulatory/business update. RNS is the best fit as a general regulatory announcement.
2011-02-28 French
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce des produits opérationnels de 4,3 millions d’euros pour 2010
Earnings Release Classification · 95% confidence The document is a press release dated February 4, 2011, announcing the operational revenue for the fiscal year 2010 (4.3 M€) and providing key balance sheet figures as of December 31, 2010. It explicitly states the data is 'provisional; IFRS standards; unaudited' and provides a summary of financial highlights, not the full, comprehensive report. Crucially, the text contains a forward-looking statement about future reporting: 'Innate Pharma publiera ses résultats annuels 2010 le 2 mars 2011, avant marché.' (Innate Pharma will publish its 2010 annual results on March 2, 2011, before market opening). Since this document summarizes preliminary results for a period and announces the future release date of the full annual results (which would likely be the 10-K or a comprehensive IR), it fits best as an initial announcement of financial results, which corresponds to the Earnings Release (ER) category. It is not the full Annual Report (10-K) itself, nor is it a comprehensive Interim Report (IR) as it covers the full fiscal year, albeit preliminarily. FY 2010
2011-02-04 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces an operating revenue of 4.3 million euros for the year 2010
Earnings Release Classification · 98% confidence The document is titled "INNATE PHARMA REPORTS ANNUAL OPERATING REVENUE OF 4.3 MILLION EUROS FOR 2010" and provides key financial highlights (operating revenue, turnover, cash position) for the fiscal year ended December 31, 2010. It explicitly states that the data is "(IFRS unaudited provisional data)". This format, focusing on key results for a full year, strongly suggests an Earnings Release (ER) rather than the comprehensive 10-K. Furthermore, the text contains a crucial sentence: "*Innate Pharma will announce its annual results on March 2, 2011, before market opens.*" This indicates the current document is the preliminary announcement of results, which aligns perfectly with the definition of an Earnings Release (ER) – the initial announcement of periodical financial results (key highlights only). It is not the full Annual Report (10-K) or the subsequent detailed report announcement (RPA). FY 2010
2011-02-04 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.